↓ Skip to main content

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

Overview of attention for article published in Journal of Neuro-Oncology, October 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

patent
9 patents
wikipedia
1 Wikipedia page

Citations

dimensions_citation
278 Dimensions

Readers on

mendeley
168 Mendeley
Title
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy
Published in
Journal of Neuro-Oncology, October 2011
DOI 10.1007/s11060-011-0737-8
Pubmed ID
Authors

Whitney B. Pope, Robert M. Prins, M. Albert Thomas, Rajakumar Nagarajan, Katharine E. Yen, Mark A. Bittinger, Noriko Salamon, Arthur P. Chou, William H. Yong, Horacio Soto, Neil Wilson, Edward Driggers, Hyun G. Jang, Shinsan M. Su, David P. Schenkein, Albert Lai, Timothy F. Cloughesy, Harley I. Kornblum, Hong Wu, Valeria R. Fantin, Linda M. Liau

Abstract

Mutations of the isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2) are commonly found in primary brain cancers. We previously reported that a novel enzymatic activity of these mutations results in the production of the putative oncometabolite, R(-)-2-hydroxyglutarate (2-HG). Here we investigated the ability of magnetic resonance spectroscopy (MRS) to detect 2-HG production in order to non-invasively identify patients with IDH1 mutant brain tumors. Patients with intrinsic glial brain tumors (n = 27) underwent structural and spectroscopic magnetic resonance imaging prior to surgery. 2-HG levels from MRS data were quantified using LC-Model software, based upon a simulated spectrum obtained from a GAMMA library added to the existing prior knowledge database. The resected tumors were then analyzed for IDH1 mutational status by genomic DNA sequencing, Ki-67 proliferation index by immunohistochemistry, and concentrations of 2-HG and other metabolites by liquid chromatography-mass spectrometry (LC-MS). MRS detected elevated 2-HG levels in gliomas with IDH1 mutations compared to those with wild-type IDH1 (P = 0.003). The 2-HG levels measured in vivo with MRS were significantly correlated with those measured ex vivo from the corresponding tumor samples using LC-MS (r (2) = 0.56; P = 0.0001). Compared with wild-type tumors, those with IDH1 mutations had elevated choline (P = 0.01) and decreased glutathione (P = 0.03) on MRS. Among the IDH1 mutated gliomas, quantitative 2-HG values were correlated with the Ki-67 proliferation index of the tumors (r ( 2 ) = 0.59; P = 0.026). In conclusion, water-suppressed proton ((1)H) MRS provides a non-invasive measure of 2-HG in gliomas, and may serve as a potential biomarker for patients with IDH1 mutant brain tumors. In addition to 2-HG, alterations in several other metabolites measured by MRS correlate with IDH1 mutation status.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 168 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 2%
United Kingdom 2 1%
Czechia 1 <1%
Spain 1 <1%
Germany 1 <1%
Unknown 159 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 38 23%
Researcher 28 17%
Student > Postgraduate 13 8%
Other 12 7%
Student > Doctoral Student 10 6%
Other 34 20%
Unknown 33 20%
Readers by discipline Count As %
Medicine and Dentistry 47 28%
Agricultural and Biological Sciences 15 9%
Biochemistry, Genetics and Molecular Biology 12 7%
Neuroscience 12 7%
Engineering 11 7%
Other 22 13%
Unknown 49 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 January 2024.
All research outputs
#4,815,444
of 23,243,271 outputs
Outputs from Journal of Neuro-Oncology
#500
of 3,012 outputs
Outputs of similar age
#27,920
of 141,198 outputs
Outputs of similar age from Journal of Neuro-Oncology
#6
of 27 outputs
Altmetric has tracked 23,243,271 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,012 research outputs from this source. They receive a mean Attention Score of 4.2. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 141,198 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.